2 active not recruiting, 2 completed, 1 not yet recruiting. 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Active not recruiting 2, Completed 2, Not yet recruiting 1 |
Follow lorlatinib: new trials by email Literature Review of lorlatinib trials Research Report on lorlatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics lorlatinib, lorlatinib plus chemotherapy - NSCLC | Phase 4 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 20 | 2025-05-10 | 2025-03-25 |
| Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases Lorlatinib - Carcinoma, Non-Small-Cell Lung, Brain Metastases | Phase 4 | Active not recruiting | Guangdong Association of Clinical Trials | 41 | 2024-08-01 | 2026-04-09 |
| Lorlatinib Continuation Study Lorlatinib - Non-Small-Cell Lung Cancer, NSCLC | Phase 4 | Active not recruiting | Pfizer | 76 | 2021-12-28 | 2026-09-23 |
| Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer Lorlatinib - Carcinoma, Non-Small-Cell Lung | Phase 4 | Completed | Pfizer | 71 | 2020-09-29 | 2025-06-11 |
| Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India Lorlatinib - Advanced Non-Small Cell Lung Cancer | Phase 4 | Completed | Pfizer | 100 | 2020-08-27 | 2024-12-20 |
Carcinoma, Non-Small-Cell Lung (2) · Brain Neoplasms (1) · Carcinoma (1) · Meningeal Carcinomatosis (1)
Pfizer (3) · Guangdong Association of Clinical Trials (1) · The First Affiliated Hospital of Guangzhou Medical University (1)
India (3) · China (2) · Spain (2) · United States (2) · France (1) · Italy (1) · Japan (1) · Poland (1) · Singapore (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Jin-Ji Yang, PhD (1)
2019 (1), 2023 (1)